- NICE has decided that normally all relevant published guidance that includes the originator molecule will apply to the biosimilar medicinal product at the time it is made available for use in the NHS.
- Biosimilars will only be appraised together with the reference products as part of a Multiple Technology Appraisal.
- Recommendations will refer to the British approved name of the medicine and will not differentiate between the originator and biosimilar products. The guidance will state that treatment should be initiated with the cheapest available product.
HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.
Tuesday 6 September 2016
New NICE biosimilars policy
The official position has been published here. The main points are:
Labels:
NICE